Aim: Syndecan-1 (CD138) has most extensively been studied and correlated with many types of cancers. CD138 is mainly expressed in epithelial cells and plasma cells. Quite a few previous studies have called attention to the expression status of CD138 in EC. We aimed to determine the location of CD138 in the hyperplasia and endometrial carcinoma progression scale, and its relation with proliferation via Ki67, and to identify a new criterion in the differential diagnosis of hyperplasia-carcinoma.
INTRODUCTION
Endometrial biopsies constitute 20% of the gynecologic specimens evaluated in the pathology. The most of endometrial biopsies are performed for abnormal uterine bleeding. The common causes of abnormal uterine bleeding include endometrial hyperplasia (EH) and endometrial cancer. [1] EHs are endometrial disorders with a large spectrum ranging from benign premalignant changes. Abnormal hormone levels are responsible for these changes. In Western countries, 150,000-200,000 new EH cases of EH are diagnosed every year. They are frequently seen lesions. [2] According to the classification of the World Health Organization in 2014, hyperplasia is divided into two groups as hyperplasia without atypical and atypical hyperplasia/endometrioid intraepithelial neoplasia (AH/EIN). In hyperplasia without atypia, progression to well-differentiated endometrial carcinoma (EC) occurs in 1%-3% of women.
However, in AH/EIN, one-quarter to one-third of women with a biopsy of AH/EIN will be diagnosed with cancer at immediate hysterectomy or during the 1 st year of follow-up. Longer time increase in risk estimates varies from 14-fold in classic, early studies of AH to 45-fold in EIN studies. [3] EC is the world's 7 th most frequent malignancy with a much higher rate of incidence in well-developed countries. [4] In the United States alone, about 7350 women die from this malignancy each year. [5] There are multitudes of possible oncogenic abnormalities throughout cancer development, but EC can be characterized with a certain number of frequent genetic alterations or regulation of gene expression. Mutations and overexpression of k-ras, steroid hormone receptors, Her2/neu, and p53 are common abnormalities in EC. [6] Recent findings showed that atypical expression of cell surface proteins participating in the cell-cell or the cell-matrix interaction can cause progression of endometrial cancer. These abnormalities contribute to the altered expression of proteins involved in cell cycle regulation and survival. [7] Syndecan is a four-membered cell membrane proteoglycan that shows a heavy modification on its ectodomain with heparan sulfate (HS) glycosaminoglycan chains. As a cell surface receptor, it shows a deep involvement in both normal and pathological events by regulating the cell-cell and the cell-matrix interactions, cell migration, development, neovascularization, microbial pathogenesis, and tumorigenesis. [8] [9] [10] [11] Such functional diversity comes largely from physical and chemical properties of syndecan-1 endorsed by both the core protein and HS, which widen the pool of interacting molecules and interaction range. [10, 11] Syndecan-1 (CD138) has most extensively been studied and correlated with many types of cancers. [12] [13] [14] CD138 is mainly expressed in epithelial cells and plasma cells. [15] Previous studies have called attention to the expression status of CD138 in EC and its regulatory roles, particularly what is implicated in cellular proliferation. This is because the expression status and the cellular functions of syndecan-1 in EC still remain largely unknown. [16] W h e n C D 1 3 8 s t a i n i n g w a s p e r f o r m e d t h ro u g h immunohistochemical methods as a plasma cell marker for the diagnosis of chronic endometritis in our clinic, some gland epithelium was observed to be stained denser than other gland epithelium. Due to the different histopathological features of these glands, we aimed to determine the location of CD138 in the hyperplasia and EC progression scale, and its relation with proliferation via Ki67, and to identify a new criterion in the differential diagnosis of hyperplasia-carcinoma.
MATERIALS AND METHODS
Endometrial curettage materials examined in the pathology laboratory between 1995 and 2016 were included in the study. A total of 376 endometrial curettage materials were examined under light microscopy by a pathologist, and 30 patients from each group, in total 120 cases with proliferative and secretory phase endometrium, hyperplasia without atypical, AH, and endometrium carcinoma were included in the study during proliferative and secretory phases. Cases with limited tissue sufficiency were excluded from the study.
Paraffin-embedded sections (4 µ in thickness) from 120 endometrial tissue samples were subjected to immunostaining for CD138 and Ki67 using antibody. In brief, after deparaffinization and treatment of 3% H 2 O 2 for 5 min, the tissue samples were blocked with a 10% serum in the blocking solution for 1 h and incubated overnight at 4°C with anti-CD138 and Ki67 antibodies at 1/400 dilution in the antibody diluent.
Immunohistochemical stained preparations were examined by a pathologist under a light microscope. The level of CD138 and Ki67 immunoreactivity in endometrial cells was expressed by scoring the percentage of CD138-positive cells into four groups: 0, negative of cells stained; 1, <33% of cells stained; 2, 33%-66% of cells stained; and 3, >66% of the cells stained. [16] Statistical analysis Statistical analysis was performed using the SPSS version 20 software (IBM Corp., Armonk, NY, USA). All analyses were conducted on the basis of normality assumption. Due to the approximate values of the calculated mode, descriptive data were expressed in median and mean values for all normally distributed variables. Point biserial correlation analysis was applied. P < 0.05 was considered statistically significant.
RESULTS
Immunohistochemical methods of CD138 and Ki67 were applied to 120 cases. These preparations were examined under a light microscope. Membrane staining for CD138 was considered positive, cytoplasmic staining was considered negative, and nuclear staining for Ki67 was considered positive [ Figure 1 ].
In the examination of CD138 staining results, 90% (n = 27) of the proliferative and secretory phase samples revealed stage 3 immunostaining and 10% of them revealed stage 2 immunostaining. Stage 2 staining was observed in 36.6% (n = 11) of cases with hyperplasia without atypical, and stage 1 staining was observed in 63.4% (n = 19). In cases with AH, stage 2 was observed in 26.6% (n = 8) of the cases and stage 1 staining was observed in 73.4%. Stage 1 staining was observed in 3.34% (n = 1) of EC cases and staining was negative in 96.6% (n = 29). Statistical analysis revealed a significant and negative correlation between histopathological progression and CD138 (P < 0.01) [ Table 1 and Figures 2 and 3 ].
In the examination of Ki67 results, it was negative in 96.6% (n = 29) of the proliferative and secretory phase samples and was positive in 3.4% (n = 1). Stage 2 staining was observed in 63.4% (n = 19) of the cases with hyperplasia without atypical, 33.3% (n = 10) had stage 1, and 3.3% (n = 1) had stage 2. In atypical cases, 3.3% (n = 1) of the cases had stage 1 staining, 86.7% (n = 26) had stage 2, and 10% (n = 3) had stage 3 staining. Stage 2 staining was observed in 6.6% (n = 2) of EC cases and staining was negative in 93.4% (n = 3). Statistical analysis revealed a significant and positive correlation between histopathological progression and Ki67 (P < 0.01) [ Table 2 ].
A significant negative correlation between Ki67 and CD138 staining frequency was observed (P < 0.01).
DISCUSSION
In the present study, CD138, which is normally used to identify plasma cells, revealed different staining stages in normal hyperplasia without atypical, AH carcinoma progression in endometrial glands, and the intensity of CD138 staining decreased from normal endometrium to carcinoma progression. Ki67 proliferation index increased while the intensity of CD138 staining decreased.
Endometrial biopsies and curettage are the most common tissue specimens received in pathology laboratory. [17] Endometrial biopsy is a conventional diagnostic method still widely used to specify endometrial lesions. [18] There are some factors limiting the diagnosis in endometrial biopsy material. Some of these factors are insufficient clinical data, curettage that performed in the wrong cycle phase, unsuitable fixation of the specimen, mistakes in histopathological sampling and sectioning, and insufficient experience. [19] Therefore, markers, which may be helpful, are very important in differential diagnosis.
Hyperplasia without atypia develops from disordered proliferative endometrium. The all endometrial compartment contains variable gland densities. In some areas, the gland to stroma ratio exceeds 1. AH is a monoclonal endometrial premalignant glandular lesion prone to malignant transformation into endometrial adenocarcinoma. AH had cancer diagnosed within the 1 st year. Normal tissues (late secretory endometrium, endometrium breaks down, etc.,) and benign processes (polyp, hyperplasia without atypia, atrophic endometria) can be mistaken for AH. Distinction between AH and adenocarcinoma is of clinical importance. [20] Most importantly, for a biomarker to be of practical benefit, it must offer information which complements that already available by routine microscopy.
CD138 is a cellular proteoglycan known for its significant role in a wide range of cellular processes by interacting with a multitude of extracellular components. It is strongly believed that modifying HS chains as well as the core protein of CD138 contributes to the diverse functional nature of CD138. This is why aberrations in either expression or posttranslational modification have been drawn to CD138 in various physiological and pathological aspects. CD138 has especially been well characterized in cancers, and either loss or enhanced expression of CD138 has been correlated with the aggressive nature of cancers depending on their tissue specificity. [16] There are only a few studies on the relationship between CD138 and different system malignancies. [21] [22] [23] [24] [25] [26] In a study by Lakkam et al. about CD138 expression in the oral dysplastic epithelium, all of normal mucosa showed strong CD138 immunohistochemical expression. [27] However, dysplastic epithelium showed that immune positivity gradually decreased along with increase in the degree of dysplasia. In a study by Poblete et al. on CD138 expression in prostate cancer, CD138 expression was observed to be decreased as the Gleason score increased. [28] The expression of CD138 in carcinomas of the head and neck regions, esophagus, larynx, liver, lung, colon, and uterine cervix was related to low clinical stage, favorable outcome, and better differentiation; however, inverse results are noted in malignancies of the nasopharynx, breast, and thyroid. [21] [22] [23] [24] [25] [26] [29] [30] [31] [32] In endometrial cancer, there have been recent histological studies on endometrial tissues, suggesting that the expression of CD138 is closely correlated with the gain of carcinogenesis in the human endometrium. [16] Thereby, CD138 is known to regulate cell differentiation, proliferation, migration, and homeostasis and may be a critical molecule in maintaining viability signals in endometrial cancer. [16, [33] [34] [35] There are few studies investigating the effect of CD138 on EH and carcinoma.
In these studies, the intensity of CD138 staining was found to be increased in the process from the normal endometrium to the EC progression. In contrast to the literature, the intensity of staining in normal endometrium was observed to be the greatest in this study and gradually decreased in hyperplasia without atypical and revealed decrease in the presence of atypia. In EC, all cases were negative except of a case of stage 1 staining. As Ki67 proliferation index increased, CD138 staining intensity decreased.
CONCLUSION
Based on our study results, CD138 may be helpful in diagnostic difficulties, and benign pathologies should be considered due to the increase in staining density. Furthermore, we believe that CD138 will be an important criterion in determining the risk of malignancy in hyperplasia, and the risk of malignancy progression may increase in cases, of which intensity of staining decreases in accordance with the normal endometrium.
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